Long-Term Cardiac-Targeted RNA Interference for the Treatment of Heart Failure Restores Cardiac Function and Reduces Pathological Hypertrophy

Background— RNA interference (RNAi) has the potential to be a novel therapeutic strategy in diverse areas of medicine. Here, we report on targeted RNAi for the treatment of heart failure, an important disorder in humans that results from multiple causes. Successful treatment of heart failure is demonstrated in a rat model of transaortic banding by RNAi targeting of phospholamban, a key regulator of cardiac Ca2+ homeostasis. Whereas gene therapy rests on recombinant protein expression as its basic principle, RNAi therapy uses regulatory RNAs to achieve its effect. Methods and Results— We describe structural requirements to obtain high RNAi activity from adenoviral and adeno-associated virus (AAV9) vectors and show that an adenoviral short hairpin RNA vector (AdV-shRNA) silenced phospholamban in cardiomyocytes (primary neonatal rat cardiomyocytes) and improved hemodynamics in heart-failure rats 1 month after aortic root injection. For simplified long-term therapy, we developed a dimeric cardiotropic adeno-associated virus vector (rAAV9-shPLB) to deliver RNAi activity to the heart via intravenous injection. Cardiac phospholamban protein was reduced to 25%, and suppression of sacroplasmic reticulum Ca2+ ATPase in the HF groups was rescued. In contrast to traditional vectors, rAAV9 showed high affinity for myocardium but low affinity for liver and other organs. rAAV9-shPLB therapy restored diastolic (left ventricular end-diastolic pressure, dp/dtmin, and &tgr;) and systolic (fractional shortening) functional parameters to normal ranges. The massive cardiac dilation was normalized, and cardiac hypertrophy, cardiomyocyte diameter, and cardiac fibrosis were reduced significantly. Importantly, no evidence was found of microRNA deregulation or hepatotoxicity during these RNAi therapies. Conclusions— Our data show for the first time the high efficacy of an RNAi therapeutic strategy in a cardiac disease.

[1]  Chaoqian Xu,et al.  The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2 , 2011, Nature Medicine.

[2]  B. Byrne,et al.  AAV‐mediated knockdown of phospholamban leads to improved contractility and calcium handling in cardiomyocytes , 2008, The journal of gene medicine.

[3]  B. Pieske,et al.  Endothelin-1 enhances nuclear Ca2+ transients in atrial myocytes through Ins(1,4,5)P3-dependent Ca2+ release from perinuclear Ca2+ stores , 2008, Journal of Cell Science.

[4]  C. Croce,et al.  MicroRNA-133 controls cardiac hypertrophy , 2007, Nature Medicine.

[5]  Xiaoxia Qi,et al.  Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA , 2007, Science.

[6]  Michael T. McManus,et al.  Dysregulation of Cardiogenesis, Cardiac Conduction, and Cell Cycle in Mice Lacking miRNA-1-2 , 2007, Cell.

[7]  Woo Jin Park,et al.  Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. , 2007, Journal of molecular and cellular cardiology.

[8]  Thomas Thum,et al.  MicroRNAs in the Human Heart: A Clue to Fetal Gene Reprogramming in Heart Failure , 2007, Circulation.

[9]  H. Zeichhardt,et al.  Coxsackievirus B3 and adenovirus infections of cardiac cells are efficiently inhibited by vector-mediated RNA interference targeting their common receptor , 2007, Gene Therapy.

[10]  R. Hajjar,et al.  Transcoronary gene transfer of SERCA2a increases coronary blood flow and decreases cardiomyocyte size in a type 2 diabetic rat model. , 2007, American journal of physiology. Heart and circulatory physiology.

[11]  S. Pinkert,et al.  Highly efficient and specific modulation of cardiac calcium homeostasis by adenovector-derived short hairpin RNA targeting phospholamban , 2007, Gene Therapy.

[12]  E. Olson,et al.  A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure , 2006, Proceedings of the National Academy of Sciences.

[13]  T. Conlon,et al.  Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo , 2006, Circulation research.

[14]  Theresa A. Storm,et al.  Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  Theresa A. Storm,et al.  Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways , 2006, Nature.

[16]  R. Hajjar,et al.  Mechanical and metabolic rescue in a type II diabetes model of cardiomyopathy by targeted gene transfer. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  B. Thöny,et al.  Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer , 2006, Gene Therapy.

[18]  J. Molkentin.  Dichotomy of Ca2+ in the heart: contraction versus intracellular signaling. , 2006, The Journal of clinical investigation.

[19]  Tong Zhang,et al.  Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte excitation-transcription coupling. , 2006, The Journal of clinical investigation.

[20]  G. Dorn,et al.  The Presence of Lys27 Instead of Asn27 in Human Phospholamban Promotes Sarcoplasmic Reticulum Ca2+-ATPase Superinhibition and Cardiac Remodeling , 2006, Circulation.

[21]  G. Dorn,et al.  A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Ross,et al.  Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure. , 2005, Cardiovascular research.

[23]  Bing Wang,et al.  Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart , 2005, Nature Biotechnology.

[24]  N. Koitabashi,et al.  Phospholamban ablation by RNA interference increases Ca2+ uptake into rat cardiac myocyte sarcoplasmic reticulum. , 2004, Journal of molecular and cellular cardiology.

[25]  T. Dieterle,et al.  A recombinant antibody increases cardiac contractility by mimicking phospholamban phosphorylation , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  James M. Allen,et al.  Systemic delivery of genes to striated muscles using adeno-associated viral vectors , 2004, Nature Medicine.

[27]  J. Guerrero,et al.  Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Chrast,et al.  Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. , 2004, The Journal of clinical investigation.

[29]  Saptarsi M. Haldar,et al.  Robust Adenoviral and Adeno-Associated Viral Gene Transfer to the In Vivo Murine Heart: Application to Study of Phospholamban Physiology , 2003, Circulation.

[30]  E. Kranias,et al.  Calcium: Phospholamban: a crucial regulator of cardiac contractility , 2003, Nature Reviews Molecular Cell Biology.

[31]  Ulrike Mende,et al.  Dilated Cardiomyopathy and Heart Failure Caused by a Mutation in Phospholamban , 2003, Science.

[32]  Masahiko Hoshijima,et al.  Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery , 2002, Nature Medicine.

[33]  R. Quaife,et al.  Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. , 2002, The New England journal of medicine.

[34]  Harvard Medical School,et al.  Targeting Phospholamban by Gene Transfer in Human Heart Failure , 2002, Circulation.

[35]  R. Hetzer,et al.  Human Coxsackie-Adenovirus Receptor Is Colocalized With Integrins αvβ3 and αvβ5 on the Cardiomyocyte Sarcolemma and Upregulated in Dilated Cardiomyopathy Implications for Cardiotropic Viral Infections , 2001 .

[36]  H. Fechner,et al.  Adenovirus-based phospholamban antisense expression as a novel approach to improve cardiac contractile dysfunction: comparison of a constitutive viral versus an endothelin-1-responsive cardiac promoter. , 2000, Circulation.

[37]  M. Martone,et al.  Chronic Phospholamban–Sarcoplasmic Reticulum Calcium ATPase Interaction Is the Critical Calcium Cycling Defect in Dilated Cardiomyopathy , 1999, Cell.

[38]  U. Schmidt,et al.  Human heart failure: cAMP stimulation of SR Ca(2+)-ATPase activity and phosphorylation level of phospholamban. , 1999, The American journal of physiology.

[39]  U. Schmidt,et al.  Human heart failure: cAMP stimulation of SR Ca2+-ATPase activity and phosphorylation level of phospholamban. , 1999, American journal of physiology. Heart and circulatory physiology.

[40]  B. Byrne,et al.  Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield , 1999, Gene Therapy.

[41]  J. Guerrero,et al.  Modulation of ventricular function through gene transfer in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Jiang Li,et al.  Construction of phospholamban antisense RNA recombinant adeno-associated virus vector and its effects in rat cardiomyocytes , 2005, Acta Pharmacologica Sinica.